Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.06.2022 | Clinical study

Pfizer-BioNTech COVID-19 vaccine safe with clozapine

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Vaccination with the Pfizer-BioNTech COVID-19 vaccine [BNT162b2; tozinameran] in patients receiving clozapine does not cause severe haematological adverse events or clozapine toxicity, say authors of a research letter published in Acta Psychiatrica Scandinavica.
Literatur
Zurück zum Zitat Lim S, et al. Haematological Changes and Adverse Events Associated with BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Clozapine - Findings from an Audit Acta Psychiatrica Scandinavica : 18 May 2022. Available from: URL: http://doi.org/10.1111/acps.13443 Lim S, et al. Haematological Changes and Adverse Events Associated with BNT162b2 mRNA COVID-19 Vaccine in Patients Receiving Clozapine - Findings from an Audit Acta Psychiatrica Scandinavica : 18 May 2022. Available from: URL: http://​doi.​org/​10.​1111/​acps.​13443
Metadaten
Titel
Pfizer-BioNTech COVID-19 vaccine safe with clozapine
Publikationsdatum
01.06.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-16299-8

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Thiamazole

Case report

Multiple drugs

Case report

Lenvatinib

Case report

Antineoplastics